Community peer support for screening methamphetamine-related heart failure
Rural Community Peer Partnerships for Improving Methamphetamine-Associated Heart Failure Screening and Engagement
This study is testing a new way to help people in rural areas who have heart failure from methamphetamine use by connecting them with peer support and cardiology care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Oregon Health and Science University Academic / other |
| Locations | 1 site (Portland, Oregon) |
| Trial ID | NCT06461962 on ClinicalTrials.gov |
What this trial studies
This study aims to implement and evaluate a community peer-facilitated approach to screen for methamphetamine-associated heart failure (MAHF) and connect individuals to cardiology care in rural areas. Given the rising rates of methamphetamine use and associated heart failure in these communities, the study addresses significant barriers to accessing medical care, including stigma and distrust of healthcare providers. The intervention includes treatment as usual and telehealth cardiology services to improve engagement and outcomes for affected individuals. The feasibility and preliminary effectiveness of this approach will be assessed to inform future interventions.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who regularly use methamphetamine and show signs of potential heart failure but have not been diagnosed with heart failure.
Not a fit: Patients who have engaged in medical care for heart failure in the past six months or are currently taking heart failure medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance access to essential cardiac care for individuals using methamphetamine, potentially improving their health outcomes.
How similar studies have performed: While similar interventions have been successful in urban settings, this approach is novel in rural communities and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient-defined regular use of methamphetamine in the last year * Any methamphetamine use in the past 30 days * Age 18 years or older * No client-reported diagnosis of heart failure * Able to communicate in English * Screen positive for potential methamphetamine-associated heart failure (MAHF) defined as B type natriuretic peptide (BNP) ≥50 pg/ml, or QRS width ≥120ms, or presence of any clinical heart failure symptoms Exclusion Criteria: * Self-reported engagement in medical care for heart failure in past 6 months. * Actively taking medications for heart failure.
Where this trial is running
Portland, Oregon
- Oregon Health & Science University — Portland, Oregon, United States (Recruiting)
Study contacts
- Principal investigator: Brian Chan, MD, MPH — Oregon Health and Science University
- Study coordinator: Brian Chan, MD, MPH
- Email: chanbri@ohsu.edu
- Phone: 503-494-2010
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.